Download PDFPDF
Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Successful treatment of refractory adult Still's disease with IL-6 receptor blockade
    • Xavier Puechal, MD, PhD
    • Other Contributors:
      • CRI (Club Rhumatismes et Inflammation)

    Dear Editori,

    We have read with interest the letter of Rech et al. on 3 patients with adult's Still disease (ASD) who experienced systemic and arthritis improvement while being treated with tocilizumab (TCZ) (1).

    We would like to add that a previously published cohort study has reported the results of a tocilizumab treatment in all ASD patients treated in France with TCZ during a three-year period, after failure...

    Show More
    Conflict of Interest:
    None declared.